Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ARMP | 8-K | bearish | 6/10 | Armata Pharmaceuticals entered into a $25M secured credit facility with Innoviva at 14% interest to fund AP-SA02 develop | May 13, 2026 |
| AIMDW | 8-K | bearish | 7/10 | Ainos reported Q1 2026 revenue of $161, a 99.8% decline YoY from $106,207, with a net loss of $2.46M (improved from $3.2 | May 13, 2026 |
| JNJ | ANALYST-UPGRADE | bullish | 3/10 | Leerink Partners issued a double upgrade on May 13, 2026, moving from Market Perform to Outperform with a $265 price tar | May 13, 2026 |
| MGNX | 8-K | bullish | 7/10 | MacroGenics reported Q1 2026 revenue of $20.8M (up 57% YoY) and net loss of $36.8M, essentially in line with EPS consens | May 13, 2026 |
| PGEN | 8-K | bullish | 7/10 | Precigen reported Q1 2026 revenue of $23.3M, massively up from $1.3M a year ago, driven by $21.6M in PAPZIMEOS product r | May 13, 2026 |
| LGVN | 8-K | neutral | 3/10 | Longeveron reported Q1 2026 results in line with consensus: EPS -$0.19 matched Street estimates and revenue of $398K was | May 13, 2026 |
| OMER | 8-K | mixed | 6/10 | Omeros reported Q1 2026 results with first-ever YARTEMLEA commercial sales of $9.9M net, GAAP net income of $56.1M (vs a | May 13, 2026 |
| DERM | 8-K | bullish | 6/10 | Journey Medical reported Q1 2026 revenue of $16.0M (+21% YoY) and a GAAP net loss of $(0.08) per share, narrowing from $ | May 13, 2026 |
| AQST | 8-K | bullish | 7/10 | Aquestive reported Q1 2026 revenue of $14.4M (up 66% YoY) and a net loss of $0.07/share, well above the $-0.14 consensus | May 13, 2026 |
| ACET | 8-K | neutral | 4/10 | Adicet Bio reported Q1 2026 net loss of $20.2M ($1.88/share), narrowing from $28.2M ($4.96/share) YoY, primarily due to | May 13, 2026 |
| SPRO | 8-K | mixed | 5/10 | Spero Therapeutics reported Q1 2026 results with revenue plunging 95% to $0.3M as the Phase 3 trial ended, but net loss | May 13, 2026 |
| RCKTW | 144 | neutral | 2/10 | Gaurav Shah, an officer and director of Rocket Pharmaceuticals, filed a Form 144 notice of intent to sell 2,728 shares o | May 13, 2026 |
| AGEN | DEFA14A | neutral | 4/10 | Agenus filed a DEFA14A supplement correcting a material error in its April 30 proxy statement: the number of options eli | May 13, 2026 |
| BCRX | 144 | neutral | 2/10 | Officer Alane P. Barnes filed a Form 144 indicating intent to sell 62,500 shares of BioCryst Pharmaceuticals (BCRX), val | May 13, 2026 |
| APGE | 144 | neutral | 2/10 | Director Michael Thomas Henderson filed a Form 144 on May 13, 2026, indicating intent to sell 60,000 shares of Apogee Th | May 13, 2026 |
| GNMSF | 6-K | neutral | 2/10 | Genmab filed its updated Articles of Association as a 6-K, reflecting routine corporate governance updates including aut | May 13, 2026 |
| VTRS | COURT-RULING | bullish | 7/10 | The Federal Circuit affirmed the district court's ruling that Mylan Pharmaceuticals does not infringe Actelion's patents | May 13, 2026 |
| ONCO | PRESS-RELEASE | neutral | 3/10 | Onconetix provided a Q1 2026 operational update highlighting new clinical publications for Proclarix®, initiation of the | May 13, 2026 |
| SLXNW | 8-K | neutral | 4/10 | Silexion Therapeutics announced the initiation of GMP clinical batch manufacturing of its next-generation siRNA therapy | May 13, 2026 |
| LITS | 8-K | neutral | 3/10 | Lite Strategy, Inc. filed an 8-K with a press release for its fiscal Q3 2026 results ended March 31, 2026. The press rel | May 13, 2026 |
| FATE | 8-K | neutral | 5/10 | Fate Therapeutics reported Q1 2026 results with a net loss of $0.26 per share, slightly narrower than the $0.32 loss in | May 13, 2026 |
| IPHYF | 6-K | bearish | 8/10 | Innate Pharma reported Q1 2026 revenue of €2.6M (up from €1.2M YoY) but disclosed a cash position of only €25.4M, provid | May 13, 2026 |
| ANIP | 8-K | bullish | 7/10 | ANI Pharmaceuticals published an updated May 2026 investor presentation via an 8-K (Item 7.01), reiterating and raising | May 13, 2026 |
| AAPG | 6-K | neutral | 3/10 | Ascentage Pharma announced it will present 17 clinical advances, including 8 poster presentations, at the upcoming EHA20 | May 13, 2026 |
| SPRY | 8-K | neutral | 2/10 | ARS Pharmaceuticals appointed Donn Casale as President effective June 1, 2026, replacing CEO Richard Lowenthal who previ | May 13, 2026 |
| IPSC | 8-K | neutral | 4/10 | Century Therapeutics reported Q1 2026 results with a net loss of $21.6M vs net income of $76.6M in Q1 2025, driven by th | May 13, 2026 |
| WHWK | 8-K | bearish | 8/10 | Whitehawk Therapeutics announced an $87.5M PIPE financing, selling 4,330,866 shares at $3.92/share and 17,991,021 pre-fu | May 13, 2026 |
| TARA | 8-K | neutral | 4/10 | Protara Therapeutics reported Q1 2026 net loss of $17.8M ($0.31/sh), beating the $-0.36 consensus by ~14%. Cash stood at | May 13, 2026 |
| SPRB | 8-K | mixed | 5/10 | Spruce Biosciences reported Q1 2026 net loss of $12.3M ($(8.94)/share), missing consensus EPS of $(7.32) by 22%. Cash an | May 13, 2026 |
| XBIO | 8-K | neutral | 3/10 | Xenetic Biosciences reported Q1 2026 results with royalty revenue up 36% YoY to ~$0.8M and net loss narrowing 49% to ~$0 | May 13, 2026 |